SCHEMBL4739485

SCHEMBL4739485

CCCCC(Nc1cccc(F)c1)C(=O)NO

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.48
MMP9 P14780 1/20 0.48
CYP2D6 P10635 2/20 0.47
KCNH2 Q12809 2/20 0.47
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
ANPEP P15144 1/20 0.44
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743414 0.86 CYP2D6 (0.51) CYP2D6KCNH2
SCHEMBL4738597 0.85 HDAC3 (0.47) MMP2CYP2D6KCNH2HDAC4HDAC7
SCHEMBL8171821 0.84 ALDH1A1 (0.43) MMP2CYP2D6KCNH2HDAC4HDAC7
SCHEMBL4741450 0.84 MMP2 (0.51) MMP2MMP9CA9
SCHEMBL4739513 0.84 HDAC8 (0.48) MMP2HDAC4HDAC7HDAC5CA9
SCHEMBL4742096 0.84 HDAC4 (0.50) MMP2CYP2D6KCNH2HDAC4HDAC7
SCHEMBL4785304 0.83 CYP2D6 (0.54) MMP2MMP9CYP2D6KCNH2CA9
SCHEMBL4739412 0.83 HDAC8 (0.54) MMP2HDAC4HDAC7HDAC5CA9
SCHEMBL4738584 0.83 KDM4E (0.45) MMP2CYP2D6KCNH2HDAC4HDAC7
SCHEMBL4739458 0.82 MMP9 (0.52) MMP2MMP9ANPEPCA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242174-B2 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA LLC (US) 2012-08-14 US disclosed
US-8242174-B2 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA LLC (US) 2012-08-14 US disclosed
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA, LLC 2012-06-21 US disclosed
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning PANTHERA BIOPHARMA, LLC 2012-06-21 US disclosed
WO-2008094592-A1 HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING PANTHERA BIOPHARNA, LLC (US) 2008-08-07 WO disclosed
WO-2008094592-A1 HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING PANTHERA BIOPHARNA, LLC (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157462-A1 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning ANTXR2, AGXT, AADAC MMP2 35/4885MMP9 809/4885CYP2D6 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.